SSGJ-707 Clinical Trials (2026): 5 Studies for Advanced Non-Small Cell Lung Cancer & Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 SSGJ-707 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Advanced Non-Small Cell Lung Cancer & Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer) and 985 total planned enrollment. 1 Phase 3 SSGJ-707 trial and 4 Phase 2 are listed. 3 SSGJ-707 clinical trials are actively recruiting. Most recent activity: NCT06980272 (Dec 2028).
SSGJ-707 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | unknown | Total |
|---|---|---|---|
| P2 | 2 | 2 | 4 |
| P3 | 1 | 1 |
Recruiting SSGJ-707 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06980272 | SSGJ-707 in Advanced Non-Small Cell Lung Cancer | P3 | Advanced Non-Small Cell Lung Cancer | 420 | Jun 2025 |
| NCT06493760 | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | P2 | Metastatic Colorectal Cancer | 130 | Sep 2024 |
| NCT06522828 | A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients | P2 | Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer | 80 | Oct 2024 |
SSGJ-707 clinical trials by indication
Advanced Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06980272 | — | P3 | recruiting | SSGJ-707 in Advanced Non-Small Cell Lung Cancer |
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06522828 | — | P2 | recruiting | A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients |
Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06493760 | — | P2 | recruiting | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients |
First-line Advanced NSCLC Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06412471 | — | P2 | unknown | A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients |
NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06361927 | — | P2 | unknown | A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients |
All SSGJ-707 trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06980272 | SSGJ-707 in Advanced Non-Small Cell Lung Cancer | P3 | recruiting | 420 | Shenyang Sunshine Pharmaceutical Co., LTD. | Jun 2025 | |
| NCT06493760 | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | P2 | recruiting | 130 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sep 2024 | |
| NCT06522828 | A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients | P2 | recruiting | 80 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Oct 2024 | |
| NCT06412471 | A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients | P2 | unknown | 235 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Jul 2024 | |
| NCT06361927 | A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients | P2 | unknown | 120 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | May 2024 |
SSGJ-707 clinical trials: frequently asked questions
- How many SSGJ-707 clinical trials are there?
- 5 SSGJ-707 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are SSGJ-707 clinical trials recruiting in 2026?
- Yes — 3 SSGJ-707 trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is SSGJ-707 being studied for?
- SSGJ-707 is being studied for Advanced Non-Small Cell Lung Cancer, Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer, First-line Advanced NSCLC Patients, Metastatic Colorectal Cancer, NSCLC. The trials are grouped by indication on this page.
- What phase is SSGJ-707 in?
- SSGJ-707 clinical trials span 1 Phase 3, 4 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors SSGJ-707 clinical trials?
- The lead sponsor across the most SSGJ-707 trials is Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SSGJ-707as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: